Drugplain

ORPHENADRINE CITRATE 100 mg/1

ORPHENADRINE CITRATE · TABLET, EXTENDED RELEASE · Lupin Pharmaceuticals, Inc.

5 Recalls on Record
Plain English

ORPHENADRINE CITRATE is a tablet, extended release containing orphenadrine citrate at 100 mg/1, taken oral. Manufactured by Lupin Pharmaceuticals, Inc..

Key Facts

Brand Name
ORPHENADRINE CITRATE
Generic Name
ORPHENADRINE CITRATE
NDC Code (Product)
43386-480
Manufacturer
Lupin Pharmaceuticals, Inc.
Strength
100 mg/1
Dosage Form
TABLET, EXTENDED RELEASE
Route
ORAL
Marketing Status
Application #
ANDA040284
Marketing Start
06/19/1998

Recall History

5 Recalls on Record
Class II03/21/2022

Sandoz, Inc

CGMP Deviations:Nitrosamine impurity (NMOA) above the acceptable daily limit.

TerminatedVoluntary: Firm initiated
Class III07/11/2014

Sandoz Inc

Failed Dissolution Specifications: Product found to be out of specification (OOS) during stability testing.

TerminatedVoluntary: Firm initiated
Class II11/14/2014

Attix Pharmaceuticals

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

TerminatedVoluntary: Firm initiated
Class II07/02/2013

Aidapak Services, LLC

Labeling: Label Mixup; ORPHENADRINE CITRATE ER Tablet, 100 mg may be potentially mislabeled as OMEGA-3 FATTY ACID, Capsule, 1000 mg, NDC 40985022921, Pedigree: W002965, EXP: 6/10/2014.

TerminatedVoluntary: Firm initiated
Class II06/18/2019

Premier Pharmacy Labs Inc

Lack of Assurance of Sterility: FDA inspection found insufficient environmental controls, potential cross contamination and lack of product specific process validations that can result in a lack of sterility assurance.

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

pain64 reports
nausea52 reports
fatigue48 reports
anxiety45 reports
drug ineffective45 reports
arthralgia41 reports
headache41 reports
dizziness37 reports
diarrhoea36 reports
dyspnoea30 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE Orphenadrine citrate extended-release tablets are indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute painful musculoskeletal conditions.

Dosage & Administration

DOSAGE AND ADMINISTRATION Adults Two tablets per day; one in the morning and one in the evening.

Warnings

WARNINGS Some patients may experience transient episodes of light-headedness, dizziness or syncope. Orphenadrine may impair the ability of the patient to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle; ambulatory patients should therefore be cautioned accordingly.

Contraindications

CONTRAINDICATIONS Orphenadrine citrate extended-release tablets are contraindicated in patients with glaucoma, pyloric or duodenal obstruction, stenosing peptic ulcers, prostatic hypertrophy or obstruction of the bladder neck, cardio-spasm (mega-esophagus) and myasthenia gravis. Orphenadrine citrate tablets are contraindicated in patients who have demonstrated a previous hypersensitivity to the drug.

Adverse Reactions

ADVERSE REACTIONS Adverse reactions of orphenadrine are mainly due to the mild anticholinergic action of orphenadrine, and are usually associated with higher dosage. Dryness of the mouth is usually the first adverse effect to appear. When the daily dose is increased, possible adverse effects include: tachycardia, palpitation, urinary hesitancy or retention, blurred vision, dilatation of pupils, increased ocular tension, weakness, nausea, vomiting, headache, dizziness, constipation, drowsiness, hypersensitivity reactions, pruritus, hallucinations, agitation, tremor, gastric irritation, and rarely urticaria and other dermatoses. Infrequently, an elderly patient may experience some degree of mental confusion. These adverse reactions can usually be eliminated by reduction in dosage. Very rare cases of aplastic anemia associated with the use of orphenadrine tablets have been reported. No causal relationship has been established.

Frequently Asked Questions

What is ORPHENADRINE CITRATE used for?

ORPHENADRINE CITRATE contains ORPHENADRINE CITRATE. It is a tablet, extended release taken oral. Consult your doctor for specific uses.

Is ORPHENADRINE CITRATE a controlled substance?

ORPHENADRINE CITRATE is not classified as a controlled substance by the DEA.

What is the generic name for ORPHENADRINE CITRATE?

The generic name for ORPHENADRINE CITRATE is ORPHENADRINE CITRATE. There are 8 other brand versions of ORPHENADRINE CITRATE.

What is the NDC code for ORPHENADRINE CITRATE 100 mg/1?

The NDC (National Drug Code) for ORPHENADRINE CITRATE 100 mg/1 is 43386-480, listed by Lupin Pharmaceuticals, Inc..